Security key
26818M108
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 164,426,217
- Total 13F shares
- 177,889,364
- Share change
- +22,989,326
- Total reported value
- $3,479,399,314
- Put/Call ratio
- 221%
- Price per share
- $19.56
- Number of holders
- 231
- Value change
- +$511,413,774
- Number of buys
- 148
- Number of sells
- 85
Report period
Q4 2025
Institutions
231
Top holders
10
DYN full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Dyne Therapeutics, Inc. SEC filings
Dyne Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 26818M108
Recent filing periods:
Top shareholders of DYN - Dyne Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.8%
from 13D/G
|
9,634,909
|
$121,881,599 | — | 30 Sep 2025 | |
| Forbion Capital Fund IV Cooperatief U.A. |
13D/G
|
ForDyne B.V. |
4.8%
|
5,400,545
|
$60,000,055 | $0 | 31 Mar 2025 | |
| Atlas Venture Fund XI, L.P. |
3/4/5
13D/G
|
10%+ Owner · Atlas Venture Associates XI, L.P. |
4%
from 13D/G
|
6,562,578
|
$165,705,095 | — | 26 Feb 2024 | |
| RTW INVESTMENTS, LP |
13F
13D/G
|
Company |
1.5%
from 13D/G
|
2,890,567
|
$36,565,673 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
1.5%
from 13D/G
|
1,717,807
|
$21,730,269 | — | 30 Sep 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
9%
|
14,745,505
|
$186,489,080 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.9%
|
9,760,414
|
$123,469,238 | — | 30 Sep 2025 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
5.6%
|
9,130,465
|
$115,500,382 | — | 30 Sep 2025 | |
| FCPM III SERVICES B.V. |
13F
|
Company |
3.3%
|
5,462,846
|
$69,105,002 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
3.3%
|
5,401,916
|
$68,334,236 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.2%
|
5,268,917
|
$66,651,800 | — | 30 Sep 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2.9%
|
4,729,174
|
$59,824,051 | — | 30 Sep 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.8%
|
4,615,144
|
$58,381,572 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.2%
|
3,554,000
|
$44,958,100 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.1%
|
3,413,435
|
$43,179,952 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2%
|
3,365,245
|
$42,570,350 | — | 30 Sep 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.9%
|
3,064,000
|
$38,759,600 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.8%
|
3,013,377
|
$38,119,219 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
2,867,605
|
$36,282,012 | — | 30 Sep 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.7%
|
2,812,422
|
$35,578,000 | — | 30 Sep 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.7%
|
2,775,000
|
$35,103,750 | — | 30 Sep 2025 | |
| BRAIDWELL LP |
13F
|
Company |
1.7%
|
2,730,481
|
$34,540,585 | — | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.7%
|
2,718,105
|
$34,384,028 | — | 30 Sep 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
1.6%
|
2,674,469
|
$33,832,033 | — | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
1.6%
|
2,614,960
|
$33,079,244 | — | 30 Sep 2025 | |
| Logos Global Management LP |
13F
|
Company |
1.5%
|
2,400,000
|
$30,360,000 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.4%
|
2,314,184
|
$29,274,428 | — | 30 Sep 2025 | |
| Venrock Adviser, LLC |
13F
|
Company |
1.3%
|
2,173,913
|
$27,499,999 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
1.2%
|
2,000,000
|
$25,300,000 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,900,215
|
$24,037,719 | — | 30 Sep 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.2%
|
1,898,950
|
$24,021,718 | — | 30 Sep 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.88%
|
1,446,361
|
$18,296,467 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.86%
|
1,419,007
|
$17,950,439 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.85%
|
1,398,530
|
$17,691,404 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.85%
|
1,398,087
|
$17,687,000 | — | 30 Sep 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0.77%
|
1,262,674
|
$15,972,826 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.63%
|
1,037,568
|
$13,125,236 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.61%
|
1,007,194
|
$12,741,004 | — | 30 Sep 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.6%
|
985,828
|
$12,470,724 | — | 30 Sep 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
0.55%
|
910,919
|
$11,523,125 | — | 30 Sep 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.51%
|
833,922
|
$10,549,113 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.5%
|
829,769
|
$10,496,578 | — | 30 Sep 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.5%
|
824,061
|
$10,424,372 | — | 30 Sep 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.49%
|
800,000
|
$10,120,000 | — | 30 Sep 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.48%
|
785,915
|
$9,941,825 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.46%
|
761,112
|
$9,628,067 | — | 30 Sep 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.44%
|
729,606
|
$9,229,516 | — | 30 Sep 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.43%
|
710,044
|
$8,982,057 | — | 30 Sep 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.43%
|
702,884
|
$8,891,483 | — | 30 Sep 2025 | |
| MPM ASSET MANAGEMENT LLC |
13F
|
Company |
0.42%
|
682,376
|
$8,632,056 | — | 30 Sep 2025 |
Institutional Holders of Dyne Therapeutics, Inc. - Common Stock (DYN) as of Q4 2025
As of 31 Dec 2025,
Dyne Therapeutics, Inc. - Common Stock (DYN) was held by
231 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
177,889,364 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, STATE STREET CORP, FMR LLC, FCPM III SERVICES B.V., ADAGE CAPITAL PARTNERS GP, L.L.C., and Orbis Allan Gray Ltd.
This page lists
231
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
205
Q4 2025 holders
231
Holder diff
26
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.